Considering the anti-inflammatory properties of IL-11, a phase I open-label clinical trial investigated the efficacy of daily subcutaneous administration of recombinant human interleukin-11 (rhIL-11) in 12 patients diagnosed with psoriasis vulgaris [42]. This evidence concerns the gene IL11 and psoriasis vulgaris.